Sleep Medication in Older Adults: Identifying the Need for Support by a Community Pharmacist

Morgane Masse 1,*, Héloïse Henry 1, Elodie Cuvelier 1, Claire Pinçon 2, Margot Pavy 3, Audrey Beeuwsaert 3, Christine Barthélémé 3, Damien Cuny 4, Sophie Gautier 5, Nicolas Kambia 6, Jean-Marc Lefebvre 6, Daniel Mascaut 7, Fabrice Mitoumba 1, François Puisieux 8, Annie Standaert 9, Patrick Wier 7, Jean-Baptiste Beuscart 2, Jean Roche 10 and Bertrand Décaudin 1

Abstract: Many older adults take benzodiazepines and sedative-hypnotics for the treatment of sleep disorders. With a view to considering the possible discontinuation of hypnotics, the objectives of the present study were to describe bedtime habits and sleep patterns in older adults and to identify the sleep medications taken. An expert group developed a structured interview guide for assessing the patients’ bedtime habits, sleep patterns, and medications. During an internship in a community pharmacy, 103 sixth-year pharmacy students conducted around 10 interviews each of the present study were to describe bedtime habits and sleep patterns in older adults and to identify the sleep medications taken. An expert group developed a structured interview guide for

1 Univ. Lille, CHU Lille, ULR 7365-GRITA—Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France; heloise.henry@univ-lille.fr (H.H.); elodie.cuvelier@univ-lille.fr (E.C.); christine.barthelemy@univ-lille.fr (C.B.); nicolas.kambia-kpakpaga@univ-lille.fr (N.K.); fabrice.mitoumba@univ-lille.fr (F.M.); bertrand.decaudin@univ-lille.fr (B.D.)
2 Univ. Lille, CHU Lille, ULR2694-METRICS, Evaluation des Technologies de Santé et des Pratiques Méthodiques, F-59000 Lille, France; claude.pincon@univ-lille.fr (C.P.); Jeanbaptiste.BEUSCART@CHRU-LILLE.FR (J.B.B.)
3 Faculté de Pharmacie, Université de Lille, F-59000 Lille, France; margot.pavy@gmail.com (M.P.); audrey.beeuwsaert@gmail.com (A.B.)
4 Univ. Lille, ULR 4515-LGCoE, Laboratoire de Génie Civil et Géo-Environnement, F-59000 Lille, France; damien.cuny@univ-lille.fr
5 Inserm, UMR-S172, Center for Pharmacovigilance, CHU de Lille, Université Lille, F-59037 Lille, France; sophie.gautier@chru-lille.fr
6 Department of General Practice, University of Lille, F-50045 Lille, France; docteurjml@icloud.com
7 Association des Conseillers et des Pharmaciens Agréés Maîtres de Stage du Nord—Pas-de-Calais, 21 Rue du Pont-Neuf, F-59000 Lille, France; daniel.mascaut@univ-lille.fr (D.M.); pfwiere@aol.com (P.W.)
8 Hôpital Gériatrique Les Bateliers, Pôle de Gérontologie, CHRU de Lille, F-59000 Lille, France; Francois.PUISIEUX@CHRU-LILLE.FR
9 Univ. Lille, Inserm, CHU Lille, U1286-INFINITE—Institute for Translational Research in Inflammation, F-59000 Lille, France; annie.standaert@univ-lille.fr
10 CHU de Lille, Unité de Psychogériatrie, Pôle de Gérontologie, F-59037 Lille, France; Jean.ROCHE@chru-lille.fr
* Correspondence: morgane.masse@univ-lille.fr

Citation: Masse, M.; Henry, H.; Cuvelier, E.; Pinçon, C.; Pavy, M.; Beeuwsaert, A.; Barthélémy, C.; Cuny, D.; Gautier, S.; Kambia, N.; et al. Sleep Medication in Older Adults: Identifying the Need for Support by a Community Pharmacist. Healthcare 2022, 10, 147. https://doi.org/10.3390/healthcare10010147

Academic Editor: Georgia Trakada
Received: 8 November 2021
Accepted: 7 January 2022
Published: 13 January 2022
Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Keywords: sleep disorders; benzodiazepines; sedative-hypnotics; community pharmacy; older adults; sleep patterns

1. Introduction

Physiological sleep processes change as people age. Older adults have a longer sleep onset latency and more nocturnal awakenings. Overall, sleep in older adults is characterized by an earlier sleep phase, a reduction in the proportion of deep sleep, and the appearance of a short mid-afternoon nap [1]. Furthermore, the prevalence of sleep disorders (restless legs syndrome, parasomnia, sleep apnea, etc.) [2] and comorbid conditions that reduce sleep quality and quality of life increase with age; these difficulties are due (as least in part) to changes in circadian rhythms and lower melatonin levels [3,4].

Benzodiazepines and benzodiazepine derivatives (“Z-drugs”) target GABA receptors/pathways and are the most frequently prescribed psychotropic medications for sleep disorders [4]. The prevalence of benzodiazepine and sedative-hypnotic (BSH) use increases with the patient’s age [5]. In cases of insomnia, treatment with a BSH can reduce the sleep onset latency by a few minutes and increase the sleep period by an hour [6]. However, the broad prescription of BSHs is usually inappropriate: the prescription duration is too long, and patients may overdose by taking medication several times during the night [7]. BSHs have harmful long-term effects, such as deregulation of the sleep architecture and thus a further increase in sleep disorders. This is why BSH prescriptions are limited to 4 weeks: beyond that time, the harm outweighs the benefits [8]. Moreover, BSHs can have other harmful effects: daytime drowsiness, memory problems [9], and a nearly two-fold increase in the risk of falls [10]. Moreover, the polypharmacy often observed in older adults [11] increases the likelihood of drug interactions, adverse drug reactions (ADRs) [12–14], unplanned hospitalization, and death [15,16]. Z-drugs have been linked to an increased risk of falls and certain central nervous system (confusion, dizziness, daytime sleepiness, etc.) [10,17].

Given the high prevalence of inappropriate BSH prescriptions and the unfavorable associated risk-benefit ratio, prompt discontinuation of these sleep medications should be a health priority for older adults [18]. Discontinuation can be encouraged and facilitated by various interventions, including patient education, dose reduction, medication replacement, and psychological support [18,19]. The recent literature data suggest that pharmacist involvement can boost the deprescription of inappropriate medications [20–23].

However, psychological and pharmacological dependency on BSHs means that complete discontinuation is particularly challenging. Knowledge of the patient’s bedtime and sleep patterns, medications taken for sleep disorders and behavioral information can also facilitate discontinuation [24]. However, there are very few literature data on the patient’s bedtime and sleep patterns in older patients.

At the Lille Faculty of Pharmacy (Lille, France), the final-year internship always includes work related to patient care pathways [25,26]. In 2016, this work concerned sleep disorders in older adults.

The objectives of the present study were to describe bedtime and sleep patterns in older adults and to identify the sleep medications taken, notably with a view to prompting the patient to discuss the modification or discontinuation of hypnotic treatments with his/her family physician.

2. Materials and Methods

2.1. Study Design

This prospective, observational study was carried out between 4 January and 30 June 2016, in community pharmacies in the Nord—Pas-de-Calais region of France. One hundred and three sixth-year pharmacy student interns and their supervising community pharmacists reviewed medical records and dispensing histories; the selected patients were
then invited to attend an interview. Each student was asked to interview about 10 older adults (aged 65 and over), complaining sleep disorders and taking at least one of medications: (i) benzodiazepines (i.e., estazolam, loprazolam, lorazepam, nitrazepam, and temazepam), (ii) Z-drugs (zolpidem and zopiclone), (iii) antihistamines (i.e., hydroxyzine, alimemazine, doxylamine, and promethazine), and (iv) melatonin. Some of these hypnotics are not available outside of France. Patients treated for depression, psychosis or bipolar disorder were not included. The students invited the patients to be interviewed (with the agreement of the supervising community pharmacist) at home or at the pharmacy.

2.2. Ethical Aspects

The study was non-interventional; in line with French legislation, formal approval by an independent ethics committee was not therefore required. Prior to the interview, all the interviewees were given information about the study’s procedures and objectives and had the right to object to processing of their personal data. The interviewees also had the right to access, modify or remove their data on request at any time after the interview. The study was registered with the French National Data Protection Commission (Commission nationale de l’informatique et des libertés (Paris, France)) by the University of Lille’s (Lille, France) data protection officer.

2.3. Study Preparation

An expert working group (composed of 14 health professionals: clinical pharmacists, community pharmacists, pharmacologists, family physicians, geriatricians, and psychiatrists) drafted a number of documents required for standardized collection of the study data: (i) guidance on interviewing people and collecting information, (ii) an interview guide, and (iii) a letter for the interviewees’ family physicians.

The study preparation comprised (i) on-campus learning for the students and their supervising community pharmacists and (ii) online learning and tools. The students and their supervising community pharmacists were then trained in the use of the various documents. The interviewers also received training on sleep in older adults, sleep changes with age, medications for treating sleep disorders, ADRs, drug–drug interactions, and main contraindications for BSHs.

2.4. Interviews and Data Collection

The pharmacy students presented the project to the community pharmacy’s staff, detected potential interviewees, informed the family physician by mail or by phone, and (with the agreement of the patient and the supervising community pharmacist) made an appointment on behalf of the patient. Convenience sampling was used. The student prepared the interview using the patient’s dispensing records and conducted the interview by following the guide.

The data collection grid is provided as Supplementary Materials. It included sections on the patient’s characteristics, medical history, number of prescription medications taken, and self-medication (if applicable). Particular attention was paid to the number of hypnotics taken, the presence/absence of overlaps between prescriptions of different medications, or recent changes in dosage. We collected information on the patient’s lifestyle, sleep (regularity of bedtime habits, sleep onset time, and the number and causes of nocturnal awakenings), the time before bedtime (presence of noise, light or electronic device use, and the bedroom temperature), sleep medications (duration of treatment, initiation in hospital or not, recent dose changes, self-medication, etc.). Data were missing for certain items. The students also asked the patient whether he/she had already considered discontinuing their medication, if they were ready to discontinue, and whether the pharmacist could contact the family physician to discuss the interview. After the interview, students updated the pharmacy’s records with regard to changes in hypnotic medications (dosage changes, medication switches, etc.).
The patient’s dependency on benzodiazepines was assessed on the Cognitive Scale for Benzodiazepine Attachment (Échelle Cognitive d’Attachement aux Benzodiazépines, ECAB) and was performed only among patients on benzodiazepines [27,28]. The ECAB questionnaire consists of 10 items scored as 1 or 0. The total score for the questionnaire is obtained by adding up the points from each item. A score of 6 or more corresponds to benzodiazepine dependency.

2.5. Statistical Analysis

Quantitative variables were expressed as mean ± standard deviation (SD) or median [interquartile range (IQR)], as appropriate. Qualitative variables were expressed as the frequency (percentage).

Logistic regression analysis was used to identify independent predictors of a wish to withdraw hypnotic treatment. For each continuous variable, the log-linearity assumption was assessed with a visual inspection of the scatterplot between the empirical logits and the covariate, and was tested by comparing a model with the continuous covariate to a model including a quadratic component with an F-test for nested models. The multivariate model was built by including all predictors, using manual backward selection to reduce the model, by maximising the c-statistics. The final model was assessed with Hosmer–Lemeshow goodness of fit test. The two-sided Type I error rate was set at alpha = 0.05. All analyses were conducted with SAS software (version 9.4, SAS Institute Inc., Cary, NC, USA).

3. Results

3.1. Characteristics of the Study Population

The pharmacy students performed 960 patient interviews (with 330 men and 630 women; sex ratio: 0.52; mean ± standard deviation age: 75.1 ± 8.8). Almost half of the patients lived alone (n = 452, 47%). The most prevalent previous or concomitant conditions reported by the patients were cardiovascular disease (n = 723, 75%), dyslipidemia (n = 408, 43%), urinary disorders (n = 106, 11%), a fall in the previous 6 months (n = 192, 20%), and respiratory insufficiency (n = 75, 8%).

The median [interquartile] number of prescription medications taken daily was 6 [5–9]. Self-medication was reported by 15% of the patients (n = 145).

Nearly one-third of the patients (n = 330, 35%) stated that they had been willing at some point in the past to consider discontinuing medication. A total of 706 patients (74%) were not ready to try discontinuing and only 26% (n = 245) patients were willing at the time of the study. Only 10% (n = 94) of the patients gave their consent for the pharmacy staff to contact their family physician.

3.2. Bedtime Habits and Sleep Patterns

About 75% patients (n = 696) had at least one poor sleep habit, and more than 41% (n = 374) have two or more poor sleep habits (Table 1). Half of the patients (n = 533, 56%) had difficulty falling asleep, although 72% (n = 694) fell asleep within an hour (Figure 1). The mean ± SD sleep period was 8.5 ± 2.1 h. Almost three quarters of the patients woke up at least once at night (n = 742, 77%) (Table 2); this was mainly due to nycturia (n = 481, 51%). A total of 62% of the patients (n = 582) considered that they felt refreshed on waking, and 35% patients (n = 334) had memory problems and/or difficulty concentrating.
Table 1. Bedtime habits and sleep patterns.

|                                      | Whole Population (n = 960) | Patients Were Not Ready to Try Discontinuing (n = 706) | Patients Who Were Ready to Try Discontinuing (n = 245) |
|--------------------------------------|---------------------------|-------------------------------------------------------|------------------------------------------------------|
| **Bedtime habits**                   |                           |                                                       |                                                      |
| **Facilitators**                     |                           |                                                       |                                                      |
| Ritual before bedtime                | 694 (73%) ^1              | 510 (71%)                                             | 184 (75%)                                            |
| Large evening meal                   | 128 (13%) ^2              | 69 (10%)                                              | 59 (25%)                                             |
| Alcohol consumption                  | 268 (28%) ^1              | 159 (22%)                                             | 109 (44%)                                            |
| Tea/coffee consumption               | 123 (13%) ^1              | 73 (10%)                                              | 50 (20%)                                             |
| Disturbed by noise or light          | 194 (20%) ^2              | 135 (19%)                                             | 59 (25%)                                             |
| Screen in the bedroom                | 407 (42%) ^4              | 300 (42%)                                             | 107 (44%)                                            |
| Temperature >19 °C (66.2 F°)         | 216 (23%) ^5              | 166 (23%)                                             | 50 (20%)                                             |
| **Barriers**                         |                           |                                                       |                                                      |
| Nycturia                             | 479 (50%)                 | 342 (48%)                                             | 137 (56%)                                            |
| Stress/anxiety                       | 120 (13%)                 | 86 (12%)                                              | 34 (14%)                                             |
| Pain                                 | 95 (10%)                  | 68 (10%)                                              | 27 (11%)                                             |

Data missing: ^1 11 (1%), ^2 9 (1%), ^3 6 (1%), ^4 4 (<1%), ^5 29 (3%), ^6 5 (1%), ^7 6 (1%), ^8 7 (1%).

Figure 1. Sleep onset latency.
Table 2. Cause of nocturnal awakening. Data were missing for 9 of the 960 patients.

| Cause                      | Whole Sample (n = 960) | Patients Were Not Ready to Try Discontinuing (n = 706) | Patients Who Were Ready to Try Discontinuing (n = 245) |
|----------------------------|------------------------|-------------------------------------------------------|-----------------------------------------------------|
| Nycturia                   | 479 (50%)              | 342 (48%)                                             | 137 (56%)                                           |
| Stress/anxiety             | 120 (13%)              | 86 (12%)                                              | 34 (14%)                                            |
| Pain                       | 95 (10%)               | 68 (10%)                                              | 27 (11%)                                            |
| Nightmares                 | 66 (7%)                | 40 (6%)                                               | 26 (11%)                                            |
| Noise outside              | 65 (7%)                | 44 (6%)                                               | 21 (9%)                                             |
| Spouse                     | 57 (6%)                | 36 (5%)                                               | 21 (9%)                                             |
| Snoring                    | 46 (5%)                | 26 (4%)                                               | 20 (9%)                                             |
| Noise in the house         | 32 (3%)                | 18 (3%)                                               | 14 (6%)                                             |
| Respiratory problems, nocturnal cough | 29 (3%) | 21 (3%)                                               | 8 (3%)                                              |
| Animals/pets               | 22 (2%)                | 17 (2%)                                               | 5 (2%)                                              |
| Hot flushes                | 21 (2%)                | 11 (1%)                                               | 10 (4%)                                             |
| Gastroesophageal reflux    | 21 (2%)                | 8 (1%)                                                | 13 (5%)                                             |

3.3. Medications for Sleep Disorders

The vast majority of the patients (n = 768, 81%) had taken only one type of hypnotic medication in their lifetime; only 15% of the patients (n = 144) had tested two, and 4% (n = 36) had tested three or more. The most commonly taken hypnotics were benzodiazepine-derivatives (Z-drugs): 48% (n = 465) and 27% (n = 259) of the patients had taken used zolpidem and zopiclone, respectively (Table 3).

Table 3. Hypnotic medications.

| Current hypnotic medications [n (%)] 1 | Whole Sample (n = 960) | Patients Were Not Ready to Try Discontinuing (n = 706) | Patients Who Were Ready to Try Discontinuing (n = 245) |
|---------------------------------------|------------------------|-------------------------------------------------------|-----------------------------------------------------|
| Zolpidem                              | 461 (48%)              | 354 (50%)                                             | 107 (44%)                                           |
| Zopiclone                             | 254 (27%)              | 183 (26%)                                             | 71 (29%)                                            |
| Lormetazepam                          | 105 (11%)              | 72 (10%)                                              | 33 (13%)                                            |
| Loprazolam                            | 43 (4%)                | 30 (4%)                                               | 13 (5%)                                             |
| Estrazolam                            | 25 (3%)                | 20 (3%)                                               | 5 (2%)                                              |
| Hydroxyzine                           | 21 (2%)                | 14 (2%)                                               | 7 (3%)                                              |
| Doxylamine                            | 16 (2%)                | 14 (2%)                                               | 2 (<1%)                                             |
| Nitrazepam                            | 9 (1%)                 | 7 (1%)                                                | 2 (<1%)                                             |
| Melatonin                             | 7 (<1%)                | 5 (<1%)                                               | 1 (<1%)                                             |
| Alimemazine                           | 5 (<1%)                | 5 (<1%)                                               | 0 (0)                                               |
| Temazepam                             | 2 (<1%)                | 0 (0%)                                                | 2 (<1)                                              |
| Promethazine                          | 1 (<1%)                | 0 (0%)                                                | 1 (<1)                                              |
| Dosage in compliance with the SPC [n (%)] 2 | 729 (78%) | 543 (77%)                                             | 186 (76%)                                           |
Table 3. Cont.

|                        | Whole Sample \( (n = 960) \) | Patients Were Not Ready to Try Discontinuing \( (n = 706) \) | Patients Who Were Ready to Try Discontinuing \( (n = 245) \) |
|------------------------|-------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Duration of treatment \( (\text{months}) \) [median \( [\text{interquartile range}] \)] \(^3\) | 120 (48–180) | 108 (48–240) | 120 (36–168) |
| Dosage change by the physician in the last 6 months \( [n \%] \) \(^4\) | 126 (13\%) | 79 (11\%) | 47 (19\%) |
| Dosage change by the patient at some point \( [n \%] \) \(^5\) | 310 (33\%) | 187 (26\%) | 123 (50\%) |
| Takes at least one more dose during the night \( [n \%] \) \(^6\) | 135 (14\%) | 94 (13\%) | 41 (17\%) |
| Management of hypnotic medications by the patient him/herself \( [n \%] \) \(^7\) | 845 (88\%) | 619 (88\%) | 226 (92\%) |
| ECAB score \(^8\) \( \geq 6 \) | 89 (51\%) | 63 (9\%) | 26 (11\%) |

Data missing: \(^1\) 11 (1\%), \(^2\) 15 (2\%), \(^3\) 69 (7\%), \(^4\) 13 (1\%), \(^5\) 10 (1\%), \(^6\) 7 (1\%), \(^7\) 6 (1\%), \(^8\) 9 (5\%); Abbreviations: SPC, summary of product characteristics; ECAB, Cognitive Scale for Benzodiazepine Attachment.

About 15\% of the patients \( (n = 143) \) had started taking hypnotic medication during a hospital stay. The majority of patients took their hypnotic medication at around 10 pm \( (n = 365, 41\%) \) (Figure 2). The vast majority of patients \( (n = 559, 63\%) \) took their hypnotic medication at bedtime. The ECAB was scored for 176 of the 184 patients taking benzodiazepines; 51\% \( (n = 89) \) had an ECAB score of 6 or more and so were considered to be benzodiazepine-dependent.

Figure 2. Time at which the hypnotic medication was taken (five patients took the hypnotic medication at different times in the evening/night). Data were missing for 63 of the 960 patients.

3.4. Factors Predictive of a Potential Wish to withdrawal Hypnotic Treatment

The multivariate analysis showed that young patients, a decrease in dosage in the last 6 months, a change in dosage by the patient himself and the patient’s management of the treatment were positive factors for the patient to wish to withdrawal treatment (Figure 3).
Figure 3. Multivariate logistic regression analysis to identify factors of a wish to withdrawal hypnotic treatment.

4. Discussion

The present study described older adults’ patterns and habits with regard to sleep and hypnotic medications. The study was based on 960 interviews. More than half reported having difficulty falling asleep, despite taking hypnotic medication. However, three quarters of the patients reported falling asleep within an hour. Our study also highlighted the elevated prevalence of poor habits and patterns before going to sleep. The vast majority of patients had tested only one hypnotic medication. At the end of the interview with the pharmacy student, nearly one-third of the patients (n = 330, 35%) stated that they had been willing to potentially discontinue medication at some point in the past, 245 (26%) of the 330 were willing to potentially discontinue medication at the time of the study, but only 94 agreed that the family physician could be contacted about possible deprescribing.

In older adults, sleep is characterized by frequent nocturnal awakenings, a reduction in the amount of deep sleep, early sleep onset, and early awakening [2]. The circadian mechanism becomes less efficient, and the overnight sleep period is often less than 6.0 to 7.5 h. In our study, however, the stated sleep period was higher; the mean ± SD value was 8.5 ± 2.1. Nearly 25% of the interviewees reported that they took more than 1 h to fall asleep. This fairly long time might be due (at least in part) to lifestyle patterns that do not promote sleep.

Indeed, many interviewees did not comply with good bedtime habits known to have a significant benefit for sleep (i.e., not using a screen in the bedroom, having a bedroom temperature below 19 °C (66.2 °F), etc.) [29,30]. Our results showed that about 75% of the patients had at least one poor sleep habit. A few reminders from the pharmacist about a healthy lifestyle might improve older adults’ sleep. A US study showed that telephone counseling on nutrition, physical activity, and sleep by a pharmacist can improve short-term physical and mental scores in the Duke Health Profile [31]. Moreover, the vast majority of our interviewees woke up during the night—mainly due to nycturia. Even though about half of interviewees woke up at night because of nycturia, only one in ten of the interviewees reported urinary disorders. This point could be addressed by the pharmacist through counselling on habits that might reduce the number of awakenings and nycturia (e.g., limiting late fluid intake, changing the administration time for diuretics and other medications that can cause nycturia, etc.) [32].

Although the patients were dissatisfied with their sleep, they appeared to be very committed to the medication they were taking; 8 in 10 of the patients had only tested a single hypnotic. The median time since the first prescription was 120 months, which is excessive and did not comply with current guidelines. In order to limit the side effects of hypnotics, the prescription period in France is limited to 28 days for zolpidem, nitrazepam, lormetazepam, zopiclone, estrazolam and loprazolam and to 12 weeks for hydroxyzine. Zolpidem was the most commonly used hypnotic. However, zolpidem has been classified
as a narcotic since 2016; in order to limit the risk of abuse and misuse, the drug is subject to a controlled prescribing procedure [33]. This change led to a decrease in zolpidem prescriptions and a corresponding increase in zopiclone prescriptions. In France, it has been established that the two medications do not have the same effect: zolpidem is used to induce sleep, whereas zopiclone is used to maintain it [34]. The long-observed time since treatment initiation and the low number of patients with a recent dose change (126 of out 947, 13%) also reflects a lack of reassessment of a medication with many side effects. Half of the patients in our study were considered to be benzodiazepine-dependent, according to the ECAB score [27].

Melatonin and doxylamine are not related to benzodiazepines and so the prescription durations are not limited. Nevertheless, the two drugs should be used for short periods only. Sleep quality can be improved by changes in habits and patterns and not necessarily by medications. Doxylamine is present in many sleep medications but is classified as potentially inappropriate for older adults [18]. Although this medication is available over the counter, its use must be supervised by pharmacists [35].

One of our study’s most important findings was that about 15% of the hypnotic medications had been initiated during a hospital stay. Hospitalization can disturb sleep in older adults, due to environmental stimuli (such as noise or light exposure) and health problems [36]. However, the prescription for hypnotic medication was typically renewed after discharge from hospital, with no reassessment. This finding emphasizes the importance of re-evaluating medications on discharge for patients who were not previously being treated with hypnotics.

Another notable study finding concerned the patient’s willingness to discontinue the hypnotic medication. This is sometimes difficult for patients to envisage: only one third reported having already considered discontinuing their medication, and less than 25% patients felt ready to discontinue. Support and education are essential for successful discontinuation [23,37]. Martin et al. [23] showed that over-65 patients being followed up with an educational intervention were significantly more likely to discontinue benzodiazepine use than those without this follow-up. Cooperation between the family physician and the pharmacist is therefore essential for helping patients to discontinue BSHs [38]. Several studies have shown that a structured, personalized intervention helps to discontinue long-term benzodiazepine use [39,40]. However, only a small proportion of our interviewees authorized the community pharmacist to contact the family physician; this highlighting the moderate level of commitment to discontinuing sleep medications. It would be interesting to perform an interventional study assessing the number of patients who actually discontinued their medication following the interview with the pharmacist. Lastly, our results support the development of pharmacist interventions based on patient-centered inter-branch approaches. These approaches must take into account the patient’s behaviors and representations and must evolve from traditional “counselling” into actual motivational interventions [38]. Indeed, motivating patients is known to be an important aspect of deprescription strategies [41]. These strategies involve discussions about deprescription among members of the healthcare team; this team must include pharmacists and physicians because BSHs are prescription-only, controlled medications.

Limitations

Our study has several limitations. Firstly, the participants were selected by pharmacy students during an internship with a community pharmacist; hence, the participants were recruited in a non-systematic way. Secondly, the interview was conducted (using a data collection grid) by pharmacy students, who do not have the experience of a senior pharmacist. Thirdly, the 6-month study duration was relatively short and prevented us from following up the patients. Fourthly, patients suffering from depression, psychosis or bipolar disorder were not included in our study, even though some were taking hypnotics. Fifthly, the study data were collected 5 years ago, and the patients’ sleep problems may have changed since then. Lastly, the study was performed in a single region of France,
and so our results might be specific for the region’s cultural setting and/or the French healthcare system—especially since BSHs are widely prescribed in France [5].

5. Conclusions

Our results show that pharmacy students and supervising community pharmacists are well placed to identify problems related to patients’ sleep disorders. Special attention should be given to the patient’s lifestyle. Another key point concerns the reassessment of hypnotic medications, particularly upon discharge from hospital; medications were rarely reassessed, and the medication use often failed to comply with the summary of product characteristics. Community pharmacists could collaborate with family physicians to facilitate the discontinuation of hypnotic medications and increase the patient’s commitment to change. A discussion with patients about their sleep patterns, nycturia and fluid intake. Greater awareness of the ADRs associated with hypnotics might help to motivate the patients in this respect.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/healthcare10010147/s1, Table S1: Data Collection Grid.

Author Contributions: Conceptualization: C.P., C.B., D.C., S.G., N.K., J.-M.L., D.M., F.M., F.P., A.S., P.W., J.-B.B., J.R. and B.D.; methodology: J.-B.B., J.R. and B.D.; validation: J.-B.B., J.R. and B.D.; formal Analysis: C.P., investigation: C.P., C.B., D.C., S.G., N.K., J.-M.L., D.M., F.M., F.P., A.S., P.W., J.-B.B., J.R. and B.D.; resources: C.P., C.B., D.C., S.G., N.K., J.-M.L., D.M., F.M., F.P., A.S., P.W., J.-B.B., J.R. and B.D.; data curation: M.M., C.P. and A.B.; writing—original draft preparation: M.M., H.H., E.C., C.P., M.P., A.B., C.B., D.C., S.G., N.K., J.-M.L., D.M., F.M., F.P., A.S., P.W., J.-B.B., J.R. and B.D.; supervision: J.-B.B., J.R. and B.D. All authors have read and agreed to the published version of the manuscript.

Funding: This study received no funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: The authors thank the patients for participating in this study. We also thank all the participating pharmacy students for their excellent work and great commitment, and the community pharmacists who supervised the students’ final-year internships.

Conflicts of Interest: The authors report no conflict of interest with regard to this research.

References
1. Dzierzewski, J.M.; Dautovich, N.; Ravyts, S. Sleep and Cognition in Older Adults. Sleep Med. Clin. 2018, 13, 93–106. [CrossRef] [PubMed]
2. Gulia, K.K.; Kumar, V.M. Sleep Disorders in the Elderly: A Growing Challenge. Psychogeriatrics 2018, 18, 155–165. [CrossRef]
3. Chen, L.; Bell, J.S.; Visvanathan, R.; Hilmer, S.N.; Emery, T.; Robson, L.; Hughes, J.M.; Tan, E.C.K. The Association between Benzodiazepine Use and Sleep Quality in Residential Aged Care Facilities: A Cross-Sectional Study. BMC Geriatr. 2016, 16, 196. [CrossRef] [PubMed]
4. Bloom, H.G.; Ahmed, I.; Alessi, C.A.; Ancoli-Israel, S.; Buysse, D.J.; Kryger, M.H.; Phillips, B.A.; Thorpy, M.J.; Vitiello, M.V.; Zee, P.C. Evidence-Based Recommendations for the Assessment and Management of Sleep Disorders in Older Persons. J. Am. Geriatr. Soc. 2009, 57, 761–789. [CrossRef] [PubMed]
5. ANSM. État Des Lieux de La Consommation Des Benzodiazépines En France Avril 2017. 2017. Available online: https://archiveansm.integra.fr/S-informer/Points-d-information-Points-d-information/Etat-des-lieux-de-la-consommation-des-benzodiazepines-Point-d-Information (accessed on 11 January 2021).
6. Holbrook, A.M.; Crowther, R.; Lotter, A.; Cotter, D.; Cheng, C.; King, D. Meta-Analysis of Benzodiazepine Use in the Treatment of Insomnia. Can. Med. Assoc. J. 2000, 162, 225–233.
7. Guthrie, B.; Clark, S.A.; McCowan, C. The Burden of Psychotropic Drug Prescribing in People with Dementia: A Population Database Study. Age Ageing 2010, 39, 637–642. [CrossRef] [PubMed]
8. Uzun, S.; Kozumplik, O.; Jakovljević, M.; Sedić, B. Side Effects of Treatment with Benzodiazepines. Psychiatr. Danub. 2010, 22, 90–93. [PubMed]
9. Guidance Leaflet. Discontinuation of Benzodiazepines and Related Medicinal Products: Procedure for the Doctor Providing Outpatient Treatment. Available online: https://www.has-sante.fr/upload/docs/application/pdf/2016-11/fiche_memo_arret_benzodiazepines_pour_mel_2015_06_16_en.pdf (accessed on 11 January 2021).

10. Treves, N.; Perlman, A.; Kolenberg Geron, L.; Asaly, A.; Matek, I. Z-Drugs and Risk for Falls and Fractures in Older Adults—a Systematic Review and Meta-Analysis. Age Ageing 2018, 47, 201–208. [CrossRef]

11. Payne, R.A.; Avery, A.J.; Duerden, M.; Saunders, C.L.; Simpson, C.R.; Abel, G.A. Prevalence of Polypharmacy in a Scottish Primary Care Population. Eur. J. Clin. Pharmacol. 2014, 70, 575–581. [CrossRef]

12. Frazier, S.C. Health Outcomes and Polypharmacy in Elderly Individuals: An Integrated Literature Review. J. Gerontol. Nurs. 2005, 31, 4–11. [CrossRef]

13. Jyrkkä, J.; Enlund, H.; Korhonen, M.J.; Sulkava, R.; Hartikainen, S. Polypharmacy Status as an Indicator of Mortality in an Elderly Population. Drugs Aging 2009, 26, 1039–1048. [CrossRef] [PubMed]

14. Calder, E.; Ferrier, J.; Gyte, G.M.; Hay, J.E.; Weller, D.F.; Williams, A.; Wynn, A.T. Benefits of Deprescribing Benzodiazepines and Other Hypnotics among Older People. Eur. J. Clin. Pharmacol. 2017, 73, 927–935. [CrossRef]

15. O’Mahony, D. STOPP/START Criteria for Potentially Inappropriate Medications/Potential Prescribing Omissions in Older People: Origin and Progress. Expert Rev. Clin. Pharmacol. 2020, 13, 15–22. [CrossRef] [PubMed]

16. Evans, D.; Pester, J.; Vera, L.; Jeanmonod, D.; Jeanmonod, R. Elderly Fall Patients Triaged to the Trauma Bay: Age, Injury Patterns, and Mortality Risk. Am. J. Emerg. Med. 2015, 33, 1635–1638. [CrossRef] [PubMed]

17. Edinoff, A.N.; Wu, N.; Ghaffar, Y.T.; Prejean, R.; Gremillion, R.; Cogburn, M.; Chami, A.A.; Kaye, A.M.; Kaye, A.D. Zolpidem: Efficacy and Side Effects for Insomnia. Health Psychol. Res. 2021, 9, 24927. [CrossRef]

18. By the 2019 American Geriatrics Society Beers Criteria®® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria®® for Potentially Inappropriately Medication Use in Older Adults. J. Am. Geriatr. Soc. 2019, 67, 674–694. [CrossRef]

19. Reeve, E.; Ong, M.; Wu, A.; Jansen, J.; Petrovic, M.; Gnijdic, D. A Systematic Review of Interventions to Deprescribe Benzodiazepines and Other Hypnotics among Older People. Eur. J. Clin. Pharmacol. 2017, 73, 927–935. [CrossRef]

20. O’Mahony, D. STOPP/START Criteria for Potentially Inappropriate Medications/Potential Prescribing Omissions in Older People: Origin and Progress. Expert Rev. Clin. Pharmacol. 2020, 13, 15–22. [CrossRef] [PubMed]

21. Westbury, J.; Jackson, S.; Gee, P.; Peterson, G. An Effective Approach to Decrease Antipsychotic and Benzodiazepine Use in Nursing Homes: The RedUSe Project. Int. Psychogeriatr. 2010, 22, 26–36. [CrossRef] [PubMed]

22. Walsh, K.A.; O’Riordan, D.; Kearney, P.M.; Timmons, S.; Byrne, S. Improving the Appropriateness of Prescribing in Older Patients: A Systematic Review and Meta-Analysis of Pharmacists’ Interventions in Secondary Care. Age Ageing 2016, 45, 201–209. [CrossRef]

23. Martin, P.; Tamblyn, R.; Benedetti, A.; Ahmed, S.; Tannenbaum, C. Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults. JAMA 2018, 320, 1889–1898. [CrossRef]

24. Hansen, C.R.; O’Mahony, D.; Kearney, P.M.; Sahm, L.J.; Cullinan, S.; Huibers, C.J.A.; Thevelin, S.; Rutjes, A.W.S.; Knol, W.; Streit, S.; et al. Identification of Behaviour Change Techniques in Deprescribing Interventions: A Systematic Review and Meta-Analysis. Br. J. Clin. Pharmacol. 2018, 84, 2716–2728. [CrossRef] [PubMed]

25. Belaiche, S.; Mercier, E.; Cuny, D.; Kambia, N.; Wierre, P.; Bertoux, E.; Mascaut, D.; Azar, R.; Bataille, P.; Bourdon, F.; et al. Community pharmacists’ interventions to prevent and screen chronic kidney disease patients. Nephrol. Ther. 2017, 13, 87–92. [CrossRef] [PubMed]

26. Beuscarts, J.-B.; Petit, S.; Gautier, S.; Wierre, P.; Balcaen, T.; Lefebvre, J.-M.; Kambia, N.; Bertoux, E.; Mascaut, D.; Barthélémy, C.; et al. Polypharmacy in Older Patients: Identifying the Need for Support by a Community Pharmacist. BMC Geriatr. 2019, 19, 277. [CrossRef] [PubMed]

27. Cognitive Scale for Benzodiazepine Attachment (HAS). Available online: https://has-sante.fr/upload/docs/application/pdf/2019-09-10-9_ecab_scale_vf.pdf (accessed on 11 January 2021).

28. Pelissolo, A.; Maniere, F.; Boutges, B.; Allouche, M.; Richard-Berthe, C.; Corruble, E. Troubles anxieux et dépressifs chez 4 425 patients consommateurs de benzodiazépines au long cours en médecine générale. L’Encéphale 2007, 33, 32–38. [CrossRef]

29. Gooneratne, N.S.; Vitiello, M.V. Sleep in Older Adults: Normative Changes, Sleep Disorders, and Treatment Options. Clin. Geriatr. Med. 2014, 30, 591–627. [CrossRef]

30. Naccache, F.; Vorspan, F. Stratégies de sevrage de benzodiazépines en ambulatoire. Revue de la littérature. Presse Médicale 2018, 47, 899–912. [CrossRef]

31. Bingham, J.; Axon, D.R.; Scovis, N.; Taylor, A.M. Evaluating the Effectiveness of Clinical Pharmacy Consultations on Nutrition, Physical Activity, and Sleep in Improving Patient-Reported Psychiatric Outcomes for Individuals with Mental Illnesses. Pharmacy 2019, 7, 2. [CrossRef]

32. Pesothen, J.S.; Cartwright, R.; Vernooij, R.W.M.; Aoki, Y.; Agarwal, A.; Mangera, A.; Markland, A.D.; Tsui, J.F.; Santti, H.; Griebling, T.L.; et al. The Impact of Nocturia on Mortality: A Systematic Review and Meta-Analysis. J. Urol. 2020, 203, 486–495. [CrossRef]
33. Prescription Obligatoire Du Zolpidem Sur Ordonnance Sécurisée—Point d’Information—ANSM: Agence Nationale de Sécurité Du Médicament et Des Produits de Santé. Available online: https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Prescription-obligatoire-du-zolpidem-sur-ordonnance-securisee-Point-d-Information (accessed on 17 January 2021).

34. Chambost, E.; Chappuy, M. Impact de la nouvelle réglementation du zolpidem—Enquête dans la circonscription départementale du Rhône. Pharm. Hosp. Clin. 2018, 53, 288–300. [CrossRef]

35. Abraham, O.; Schleiden, L.; Albert, S.M. Over-the-Counter Medications Containing Diphenhydramine and Doxylamine Used by Older Adults to Improve Sleep. Int. J. Clin. Pharm. 2017, 39, 808–817. [CrossRef]

36. Arora, V.M.; Stewart, N. Sleep in Hospitalized Older Adults. Sleep Med. Clin. 2018, 13, 127–135. [CrossRef]

37. Kuntz, J.L.; Kouch, L.; Christian, D.; Hu, W.; Peterson, P.L. Patient Education and Pharmacist Consultation Influence on Nonbenzodiazepine Sedative Medication Deprescribing Success for Older Adults. Perm. J. 2019, 23, 18–161. [CrossRef] [PubMed]

38. Pottie, K.; Thompson, W.; Davies, S.; Grenier, J.; Sadowski, C.A.; Welch, V.; Holbrook, A.; Boyd, C.; Swenson, R.; Ma, A.; et al. Deprescribing Benzodiazepine Receptor Agonists: Evidence-Based Clinical Practice Guideline. Can. Fam. Physician Med. Fam. Can. 2018, 64, 339–351.

39. Darker, C.D.; Sweeney, B.P.; Barry, J.M.; Farrell, M.F.; Donnelly-Swift, E. Psychosocial Interventions for Benzodiazepine Harmful Use, Abuse or Dependence. Cochrane Database Syst. Rev. 2015, CD009652. [CrossRef] [PubMed]

40. Ten Wolde, G.B.; Dijkstra, A.; van Empelen, P.; van den Hout, W.; Neven, A.K.; Zitman, F. Long-Term Effectiveness of Computer-Generated Tailored Patient Education on Benzodiazepines: A Randomized Controlled Trial. Addict. Abingdon Engl. 2008, 103, 662–670. [CrossRef]

41. De Souza Ribeiro, P.R.; Schlindwein, A.D. Benzodiazepine Deprescription Strategies in Chronic Users: A Systematic Review. Fam. Pract. 2021, 38, 684–693. [CrossRef]